← 返回首页
美国 · 通讯社与实时数据 · PR Newswire

Novo's Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026

来源:PR Newswire · 美国 1 小时前
Novo's Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026
PR Newswire

详细摘要

Statistically significant reductions in food noise scores from baseline were observed in adults taking semaglutide injection within the first month of initiation and through six…

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 14, 2026 /PRNewswire/ -- Today, Novo Nordisk presented real-world findings from the SIGNAL and OCTANE studies at ObesityWeek® 2026, looking at how food noise scores changed for adults with overweight or obesity taking Wegovy® injection or Wegovy® pill.1,2 Both retrospective cohort analyses used de-identified patient data from the Ro telehealth platform and a validated seven-item questionnaire to assess food noise, defined as persistent, intrusive and unwanted thoughts about food.3

"Patients at our center often describe persistent and intrusive thoughts about food, and that managing those thoughts can take a toll on their day-to-day lives," said Louis J. Aronne, MD, Director of the Comprehensive Weight Control Center, Weill Cornell Medicine, and co-author of the studies. "The SIGNAL and OCTANE findings showed that semaglutide injection and oral semaglutide were associated with early reductions in food noise in real-world studies. Looking forward, additional research can help clarify the clinical relevance of such food noise and its place in everyday obesity care."

The two presented studies examined changes in patient-reported food noise scores over time among adults with overweight or obesity taking semaglutide in a real-world telehealth setting, using the validated seven-item Ro Allison Indiana Dhurandhar–Food Noise Inventory (RAID-FN) questionnaire, which measures persistent, intrusive and unwanted thoughts about food.1,2

In the SIGNAL study, 26,213 treatment-naïve adults with obesity or overweight with at least one weight-related condition initiating semaglutide injection were followed for up to six months in a real-world telehealth setting.1 The adjusted mean baseline RAID-FN total score was 2.72 (95% CI: 2.71, 2.74).1 Mean food noise scores decreased within the first month, with an adjusted mean change from baseline of -0.42 points (95% CI: -0.43, -0.41).1 The greatest reductions were observed during the first three…

In…

"…

文章开头,摘自PR Newswire。如需阅读全文,请前往媒体网站。

在 PR Newswire 阅读全文 登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.prnewswire.com)

推荐阅读